Raymond Tasch Ramirez, MD
Family Medicine · Bayamon, PRNPI 1497727341
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 33.4% of the total. Reporting peaked in 2023 at $443 and has fallen 83.1% since, to $75 in 2025. Among family medicine clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $32.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$538
- Boehringer Ingelheim$351
- Eli Lilly Export S.A. Puerto Rico Branch$195
- Johnson & Johnson$138
- Lilly USA, LLC$119
- Merck$93
- plus $178 from 5 others
What the payments were for
- Food & beverage$1,611100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $538 |
| Boehringer Ingelheim | 13 | $351 |
| Eli Lilly Export S.A. Puerto Rico Branch | 9 | $195 |
| Johnson & Johnson | 6 | $138 |
| Lilly USA, LLC | 1 | $119 |
| Merck | 5 | $93 |
| PBG Puerto Rico LLC | 3 | $70 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| GSK | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,611 in reported general payments places this provider in the 90th percentile of 497 family medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $86,787 |
| XareltoRivaroxaban | 102 | $71,487 |
| NuplazidPimavanserin Tartrate | 12 | $60,334 |
| TradjentaLinagliptin | 77 | $57,329 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $52,818 |
| JanuviaSitagliptin Phosphate | 50 | $50,283 |
| SynthroidLevothyroxine Sodium | 548 | $47,717 |
| FarxigaDapagliflozin Propanediol | 53 | $43,594 |
| JardianceEmpagliflozin | 51 | $39,209 |
| GlyxambiEmpagliflozin/Linagliptin | 51 | $36,298 |
| JentaduetoLinagliptin/Metformin Hcl | 47 | $28,013 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 30 | $19,466 |
| OzempicSemaglutide | 14 | $13,546 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $11,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Glyxambi, Jentadueto, Trijardy Xr | $351 | $180,316256 claims |
| MerckJanumet, Januvia | $93 | $103,101119 claims |
| Johnson & JohnsonXarelto | $138 | $71,487102 claims |
| AbbVieSynthroid | $20 | $47,717548 claims |
| AstraZenecaFarxiga | $538 | $43,59453 claims |
| GSKTrelegy Ellipta | $25 | $11,44117 claims |
| Sanofi-aventis U.S. LLCLantus | $25 | $9,12973 claims |
| Lilly USA, LLCHumalog Mix 75-25 | $119 | $4,29419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 497 family medicine providers in Puerto Rico.
Other family medicine in Bayamon
- Marcelino Cintron PontonBayamon$3K
- Eddie Ortiz RiveraBayamon$3K
- Veronica Perez RamosBayamon$2K
- Jorge MeauxBayamon$2K
- Carmen CabreraBayamon$2K
- Kathy Caraballo RiveraBayamon$2K
- Sergio ChevereBayamon$1K
- Lizette Santiago ColonSan Juan$279K
- Ivan Melendez-RiveraPonce$183K
- Beigno GonzalezSan Juan$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.